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Absorption, Metabolism, and Excretion of
Di(2-ethylhexyl) Phthalate by Rats and Mice
by Phillip W. Albro*
There is convincing evidence in the literature that most of the adverse biological effects of phthalate
diesters are actually effects ofmetabolites rather than ofthe parent compounds. Ifso, the dramatic species
differences in endpoint metabolic profiles make it essential that metabolism ofphthalates be understood in
detail, including the factors that may alter the metabolism. A metabolic pathway for phthalates having
saturated alkyl groups has been postulated based on identification of metabolites produced in vivo and
excreted in urine. The first few steps in the postulated pathway have been confirmed in vitro using enzy-
matically active preparations from rats and mice; some details of the nature ofthese early steps have been
learned. Although some information concerning later steps is available, much remains to be learned in this
area. Species differences are postulated to involve kinetics of several biochemical and physiological events
acting in concert or competition. Among these interacting factors are competition ofat least three enzymes
for phthalate monoesters as substrate, relative kidney clearance rates for different metabolites, relative Km
values of oxidative enzymes for the same precursors in different species, and relative equilibria between
glucuronide formation and hydrolysis.
Essential information that must be obtained in the future includes (a) which metabolites play a causal
role in which biological effects, and (b) what factors (age, diet, state of health, etc.) can modify the
metabolism of phthalate esters and in what way.
Introduction
Presentlyavailable evidence strongly suggeststhatthe
undesirable biological effects ofphthalate esters are me-
diated by metabolites rather than by the parent com-
pounds in vivo. Such effects as testicularatrophy (1) and
peroxisome proliferation in rodents (2) are also seen on
administration of the primary hydrolysis products of
phthalate esters (3-5). Effects produced by, e.g. di(2-
ethylhexyl) phthalate (DEHP) on mitochondrial function
and energy metabolism in vivo are also produced (in
vitro) by either mono-2-ethylhexyl phthalate or 2-ethyl-
hexanol or their oxidation products (6,7). Oral exposure
to less than massive amounts of DEHP, the most thor-
oughly studied ofthe phthalate diesters, does not result
in exposure ofinternal organs to intact diester since hy-
drolysis is very rapid in lung and intestines (8,9). The
organs that are most likely to be exposed to high levels
of intact phthalate diester-skin and gastrointestinal
tract-are not considered target organs for adverse bi-
ological effects.
It is important to recall that at this point in time no
biological effect ofphthalate diesters has been linked to
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any specific metabolite. The primary metabolites (mono-
ester and alcohol) are each rapidly oxidized to a variety
of more polar products in vivo (10,11) and in vitro (12),
any or all of which products may be biologically active.
None of these polar metabolites have been tested indi-
vidually for their biological effects, as none of them (ex-
cept 2-ethylhexanoic acid) (13) is commercially available
in quantities sufficient for testing.
The excreted metabolites of DEHP consist primarily
ofterminal oxidation products (diacids, ketoacids) in ur-
ine from rodents (rats and mice), but primarily ofunox-
idized or minimally oxidized (mono-2-ethylhexyl phthal-
ate, hydroxyacid) products in urine from primates
(African green monkey, humans) (14). Besides the dra-
maticspeciesdifferences, therearealsomajordifferences
between both elimination rates and metabolic proffles
whenyoung and old animals ofthe same species are com-
pared (10,15).
For these reasons it is essential that the metabolism
of phthalate esters be understood in some detail. The
possibility exists that the adverse biological effects of
some phthalate esters, even including the tumor pro-
motion by DEHP (16), may be associated with metabo-
lites not produced to a significant extentby some species
(such as humans), or only produced by members of a
species whose metabolic capabilities have been altered
by age, disease, or exposure to enzyme inducers. TheP W ALBRO
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FIGURE 1. Absorption of DEHP in mice. Single oral (gavage) doses
of[7-14C]-DEHP were given to CD-1 or B6C3F mice in corn oil in
triplicate. The levels of 14C-DEHP 6 hr later were determined in
the livers by extraction, chromatography on Florisil, and pre-
parative TLC as described previously (14).
first step in comprehending these relationships is to elu-
cidate the metabolism ofphthalate esters in normal an-
imals, which is the subject ofthe present paper. Factors
that can alter metabolism and identification of the par-
ticular metabolites responsible for particular biological
effects remain essential studies for the future.
Absorption Thresholds
We have previously reported (14) that there is a rela-
tively discrete threshold forsingle oraldosages ofDEHP
in rats, below which intact diester does not reach the
liver but above which there is arapidly increasing dose-
dependentabsorptionofintactdiester. Attemptstodetect
such aphenomenon in mice did not give clear-cut results
(Fig. 1). There may have been such a threshold in CD-1
random-bred mice, but, ifso, it was at such ahigh dose
level that we had only a sinle experimental point above
that level in the study. In contrast, there did not appear
tobe athreshold effect inB6C3F1 mice. Levels ofintact,
"4C-labeled DEHP reaching the livers was a dose-de-
pendent, nearly linear function of admiIiistered DEHP
between 20 mg/kg and 575 mg/kg. Levels of "4C-DEHP
in the livers were measured 6 hr afterdosing, since that
was the time at which total 14C in the livers was maxi_
mum. AnapparentabsorptionthresholdforintactDEHP
may exist in Fischer 344 rats (14) and CD-1 mice, but
the evidence does not support the existence of one in
B6C3F1 mice.
Carcinogenesis bioassays ofDEHP in rats have in the
past been negative when dosage levels were below the
apparent threshold for absorption of intact diester (17)
and positive in the only reported bioassay to exceed this
threshold (18) and persist above it for two years. DEHP
was positive inacarcinogenesis bioassayinB6C3F1 mice
(18), the species in which we do not find an absorption
threshold (i.e., intact DEHP would be absorbed to some
extent even at relatively low doses). Thus the possibility
existsthatintactDEHP(asdiester)mustreachthelivers
ofrats and mice in order to produce carcinogenesis, but
the available data are inconclusive. There are no data
available concerningpossible absorptionthresholds inhu-
mans. However, human exposure to DEHP is often via
blood transfusions (19), in which case one would indeed
expect intact DEHP to reach the liver. This would not
constitute a chronic exposure in most cases, so the rel-
evance to potential carcinogenesis is unclear.
Intermediary Metabolism
The conversion of phthalate diesters to water-soluble
excretionproductsinvolvesmorethanonemetabolicpath-
way. The pathway followed by phthalate esters whose
alcoholportions containanaliphaticdoublebondisclearly
different from that followed by the more common phthal-
ate plasticizers having saturated aliphatic chains (20).
Only the latter will be considered here. Although the
basic steps in the pathway are probably the same for a
variety of phthalate diesters (21), the spectrum of me-
tabolites is especially complex in the case ofDEHP (be-
cause ofthe branched chains). Therefore DEHP will be
emphasized to illustrate metabolic capabilities.
Rats and mice differ in their elimination of DEHP
metabolites most conspicuously in that mice excrete the
oxidation products mainly in the form ofglucuronide con-
jugates, while rats (several strains) do not appear to
excrete DEHP metabolites as conjugates (14). It should
be noted, however, that rats do excrete glucuronide con-
jugates of the metabolites of di(n-butyl) phthalate (22).
Withthis exception inthe case ofrats, there is no reason
to suspect that functionally equivalent pathways for me-
tabolism ofDEHP differ significantly in any higher spe-
cies from fish (23) to humans (24). What differences exist
appeartobe quantitative ratherthanqualitative, except
possibly in the detailed stereochemistry of some of the
enzymes involved (10).
The obligatory first step in the metabolism of DEHP
is hydrolysis to MEHP plus2-ethylhexanol. Atleast 98%
of the 1 C present in urine of rats given carbonyl-"4C-
labeledDEHPeitherorallyorIV(25)hasbeenaccounted
for in the form of some 20 metabolites, none of which
retained both ester functions (10). Moreover, it has been
reportedthatalloftheurinarymetabolites of14C-DEHP
are also found (14C-labeled) in urine of rats given 14C-
MEHP (10). In addition to the 20 known metabolites of
DEHP derived from MEHP and retaining the o-phthal-
ate moiety (10), at least seven metabolites produced by
rats from 2-ethylhexanol have been identified (11). Since
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Table 1. Distribution of DEHP hydrolase activity in various
tissues of CD rats.a
DEHP hydrolase
Tissue homogenate U/mg protein U/g tissue
Intestinal mucosa 0.86 83
Liver 0.48 144
Kidney 0.15 45
Lung 0.07 15
Plasma 0.27 17
Pancreas 54.9 34,400
Skin 0.41 15
Adipose 0.23 1.4
aHydrolysis of DEHP to MEHP followed radiochemically at the
pH optimum for each tissue, using cholate-solubilized DEHP. One
unit corresponds to the hydrolysis of 1 nmole/min at 37°C. Data of
Albro and Thomas (8).
the carbon chain of 2-ethylhexanol is ultimately capable
ofbeing metabolized to C02 (11,26), only the metabolites
derived from MEHP will be considered in what follows.
The enzyme(s) responsible forthe hydrolysis ofDEHP
to MEHP and 2-ethylhexanol is (are) found in all tissues
surveyed (Table 1) but especially in the pancreas (8). The
enzyme (trivialname, nonspecific lipase, E.C. 3.1.1.-) has
been purified from rat pancreas and its catalytic mech-
anism determined (27). The enzyme requires that the
ester substrate be presented in the form of an anionic
micelle (28), and can carry the hydrolysis of DEHP to
completion (no product inhibition). MEHP is not hydro-
lyzed to phthalic acid by this enzyme. The only esterase
thus far reported that will accept MEHP as substrate
was located in liver microsomes (8), and is presumably
responsible for the production ofthe very minor amount
of free phthalic acid found in rat urine (14) and the con-
siderably greater amount found in mouse urine (14) fol-
lowing administration of DEHP
Following hydrolysis ofDEHP, MEHP undergoes a se-
ries ofoxidations in vivo as summarized in Figure 2 (10).
Only the side chain of MEHP is shown in the figure;
there appears to be no alteration ofthe aromatic ring in
mammals (10). Figure 2 is intended to show metabolic
relationships only; it should not be taken as a specific
pathway. Thecurrentlypostulatedfunctionalpathwayfor
metabolism ofDEHP in rodents is illustrated in general
terms in Figure 3. ComparisonofFigures 2 and3reveals
that, because ofthe existence oftwo chain terminations
on the ethylhexylmoiety, several distinctmetabolites can
result from each type ofmetabolic process. Characteri-
zation of the individual metabolites has been presented
previously (10) and will not be belabored here.
The second stage in the (oxidative) metabolism of
DEHP, introduction of hydroxyl groups at various posi-
tions of the C-8 side chain of MEHP, is catalyzed by
NADPH-dependent microsomal monooxygenases analo-
gous (or identical) to the cytochrome P-450 associated
fatty acid w- and (w - 1) hydroxylases (12). This activity
has been measured in rat liver and kidney and rabbit
lung (but not rat lung), as summarized in Table 2. Se-
lective effects of inhibitors and inducers, plus determi-
nation of kinetic constants, indicated that at least two
different monooxygenases act on MEHP in rat liver (12).
1 2 3 4 5 6
-OCH2-CH-CH2-CH2-CH2-CH3
CH2-C H3
7., 8
8-OH
VIl
8- COOH
IV
7-COOH
U
5-OH-8-COOH
XXI
5-keto-8-COOH*
XXV
4-keto
xII
4,6- diOH
xx
4-OH- 8-COOH
XVIII
4- ketoS8-COOH
xIv
6 -COOH
v
5 -COOH
4-OH-6-COOH
XVI
4-keto-6-COOH
xv
4- COOH
FIGURE 2. Metabolites produced from MEHP by rats in vivo and excreted in the urine. Only the ethylhexyl chain and its metabolic alterations
are shown, but it should be assumed that the chain is esterified to one of the two carboxylate groups of o-phthalic acid (10).
7-OH
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FIGURE 3. Postulated pathway for metabolism ofDEHP in mammals: (1) nonspecific lipase; (2) esterase (primarily microsomal); (3) microsomal
monooxygenase + NADPH + 02; (4) alcohol dehydrogenase + NAD (cytosolic); (5) aldehyde dehydrogenase + NAD; (6) ,B-glucuronidase
(reaction substrate may also involve other metabolites); (7) UDP-glucuronyltransferase + UDPG (may also accept other metabolites as
substrates); (8) a-oxidation enzymes and cofactors, mitochondria; (9) P-oxidation enzymes and cofactors, mitochondria and/or peroxisomes.
This enzyme system has not been studied in microsomes
from mice as yet.
Hydroxylation ofMEHP is in direct competition with
hydrolysis to phthalic acid by microsomal esterase (Fig.
3) and also with conjugation by UDP-glucuronyltrans-
ferase. In spite of the fact that rats do not excrete de-
tectable amounts of DEHP metabolites in the form of
glucuronides, microsomes from both rats and mice cat-
alyze the glucuronide conjugation ofMEHP as well as of
mono-n-butyl phthalate, as shown in Table 3. The reac-
tion involves UDP-glucuronic acid and microsomes, but
apparently no other cofactors are required. Microsomes
from CD rats are only about halfas active as those from
B6C3F1 mice when MEHP is the substrate, while both
sources of microsomes are equally active with butyl
phthalate as substrate. The reverse reaction is catalyzed
by P-glucuronidase, the level of which was much higher
in rat liver than in mouse liver (Table 4). Levels ofthis
enzyme were comparable in rat and mouse urine (29).
We are just beginning to study in detail the further
oxidation ofhydroxylated MEHP At the moment all that
can be said is that the hydroxylated metabolites are ox-
idized to keto- and carboxyl-containing products by an
enzyme or enzymes in the post-microsomal supernatant
fraction of rat liver homogenates, and that NAD is in-
Table 2. Distribution of MEHP hydroxylase activity in
uninduced microsomes from different sources.a
Hydroxylation pmole/min/mg protein
Source X w-1 w-2
Rat liver 143 542 207
Rat kidney cortex 125 223 152
Rat lung NDb ND ND
Rabbit lung 29 4 8
'Production ofmetabolites X (w), IX (w - 1), and VII (w - 2) (for
structures see Fig. 2) from MEHP in vitro with purified microsomes
in the presence ofan NADPH generating system. Taken from Albro
et al. (12) which gives details ofthe assay.
bND = none detected.
volvedinthereaction (unpublished observations). Beyond
this, there are preliminary indications of a reaction be-
tween those metabolites containing a terminal, aliphatic
carboxyl group and reduced coexzyme A in the presence
ofATP, MgCl2, and acyl coenzyme A synthetase purified
from beefliver. This reaction may be preparatory to a-
and/or ,-oxidation of the carboxy-terminated metabo-
lites as postulated in Figure 3.
Elimination-Excretion
Elimination kinetics for DEHP has been studied in
several animal species (30-32), but unfortunately the
mouseisnotoneofthem. Crudemeasurementshavebeen
made, generally at a single dose level and at a few time
points, but a careful pharmacokinetic study inthe mouse
is lacking, so rat and mouse can not be compared in this
regard.
Metabolite distributions in urine tend to be character-
istic ofa given species and relatively independent ofdose
Table 3. Phthalate monoester: UDP-glucuronyltransferase
activity in microsomes from CD rats and B6C3F' mice.a
UDPG transferase
activity, pmole/min/mg
protein
Incubation conditions Rat Mouse
Complete, + MEHPb 276 447
Complete, + MBP 198 202
Minus digitonin, + MEHP 383 110
Complete, boiled microsomes, + MEHP 27
Minus UDPD, + MEHP 13
aEach tube received 0.75 mL of0.1 M Tris HCI, pH 7.4, containing
1.27mgMgCl2/mL, 0.1mLofmicrosomepreparationat10mgprotein/
mL, 0.25 M sucrose, 0.1 mL of UDP-glucuronic acid (UDPG) at 60
,umole/mL inwater, and0.1 ,uCi(0.1 ,umole) ofeitherMEHPormono-
n-butyl [7-14C]-phthalate (MBP) in 10 ,IL of DMSO. Incubation was
30 min at 3700, the formation of glucuronide conjugate being moni-
tored by radio-HPLC as described previously (29).
bThe complete system includes 0.2% digitonin as hypothetical ac-
tivator.
296ABSORPTION, METABOLISM, AND EXCRETION OF DEHP
E
0.
FIGURE 4. HPLC radiochromatograms ofdiazomethane-treated uri-
nary metabolites of DEHP from rat and mouse. Chromatography
on S5CN with anonlineargradient oftetrahydrofuran into heptane
as described previously (29).
(though not independent of route of exposure) (25). A
comparison ofthe profiles ofDEHP metabolites in urine
from CD rats and CD-1 mice is illustrated in Figure 4.
DEHP labeled with '4in the carbonyl position was ad-
ministered orally in corn oil by gavage, urine was col-
lected for 48 hr, the metabolites were stripped from aci-
dified urine using XAD-2 resin, esterified with
diazomethane, andfractionatedbyHPLC on aSpherisorb
S5CN nitrile column with a heptane:tetrahydrofuran
gradient, all as described previously (29). Fractions (30
sec each) were collected and radioassayed by liquid scin-
tillation counting to produce the profiles shown. The me-
Table 4. Levels of 3-glucuronidase activity in liver and urine of
CD rats and B6C3F1 mice'.
1-glucuronidase activity, nmole/minb
Liverc Urine
Rats 4.18 2.83
Mice 1.57 3.66
aUsing phenolphthalein glucuronide as substrate at pH 4.5, 37°C,
means ofthree animals.
bPer mg protein (liver) or per mL urine.
C20000g supernatant of 10% homogenate.
tabolite structures associated with each peak of radio-
activity were identified by gas chromatography-mass
spectrometry and formation ofcharacteristic derivatives
(10).
The mouse urine contained all the metabolites found
in rat urine, plus glucuronide ester conjugates ofmost of
them (29). However, after hydrolysis ofthe conjugates it
would be seen that the relative amounts ofdifferent me-
tabolites were quite different for the two species (Table
5). Whereas metabolite V, or 2-ethyl-5-carboxypentyl
phthalate wasbyfarthemostabundantsinglemetabolite
in rat urine, its presumed ,-oxidation product, 2-ethyl-
3-carboxypropyl phthalate predominated in the mouse
urine. This suggests that the production of glucuronide
conjugates in the mouse does not lead to rapid excretion
ofless oxidized metabolites than those excreted by rats.
The mean oxidation level ofthe urinary profile of DEHP
metabolites in the mouse is not much less than that of
the rat. Ifthis mean is expressed in terms ofthe amount
ofNAD thatmustbe reduced to produce it, the numbers
come out 2.93 mole NAD/mole phthalate in the rat and
2.23 mole/mole in the mouse. These numbers may be
contrasted with calculated values of 1.42 mole/mole for
the African green monkey and 1.48 mole/mole for human
leukemia patients.
Figure 2 also indicates that some ofthe identified me-
tabolites of DEHP have been oxidized at two points on
the ethylhexyl chain. Whether this represents a simul-
taneous attack or "recycling" is not known; we have not
succeeded in producing these metabolites in vitro.
Summary and Discussion
The metabolism of phthalate esters by a variety of
laboratory animal species is beginningto be understood,
although a number of details remain to be elucidated.
The point in the metabolic pathway at which the quan-
titative differences among species arises, at least in con-
trol animals (those not chronically exposed to phthal-
ates), wouldlogicallybethepointofthreefoldcompetition
in Figure 3. The proliferation of peroxisomes and mito-
chondria in rodents exposed chronically to DEHP (2,33),
Table 5. Comparison of metabolite distributions in urine of CD
rats and CD-1 mice 24 hr after oral administration of DEHP.
Percentage of l4ca
Metaboliteb Mouse Rat
MEHP 18.6 2.3 0.1 ± 0.1
Phthalic acid 12.4 ± 1.5 2.5 ± 0.6
I-V (diacids)c 20.0 ± 1.9 65.3 ± 7.2
VI (keto) 14.9 2.1 9.5 ± 1.0
VII-X (hydroxy) 21.6 ± 2.7 13.3 ± 1.5
XV-XX (recycled?) 11.5 ± 1.3 9.3 ± 1.1
aMean ± SD (N = 3 each) in total 24 hr urine following admin-
istration by gavage of [7-14C]-DEHP in corn oil at a dosage level of
180 mg/kg body weight in both species.
bStructrues designated by Roman numerals correspond to the
structures summarized in Figure 2 (10).
cMetabolites I and V dominate this class, amounting to 16.8 (I) and
1.1 (V) % oftotal 14C from the mice and 9.4 (I) and 50.7 (V) % from
the rats.
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althoughitshouldincreasethecapabilitiesfor1-oxidation
ofaliphatic carboxylates inthese species, cannot account
for the differences in naive animals as the 1-oxidation
enzymes increase only several days after DEHP is given.
There are implied "competitive" branch points not
shown in Figure 3 that must be considered as well. Ex-
cretion ofagivenmetabolite is always potentiallyin com-
petition with further oxidation of that metabolite. Rel-
ative kidney clearance rates, presence or absence of
highlywater-soluble glucuronide conjugates, andrelative
Km values of the oxidative enzymes of different species
must all be interacting with the competition between
those enzymes thatutilize the same substratetoproduce
the observed differences in endpoint metabolic profiles in
different animal species.
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